Interventional cardiology

Global Arteriotomy Closure Devices Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Tuesday, October 20, 2020 - 4:03pm

The "Arteriotomy Closure Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Arteriotomy Closure Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The major factors attributing to the growth of the arteriotomy closure devices market are increasing incidences of vascular disorders and rising geriatric population.
  • Patient comfort and satisfaction are the important factors that result in wide adoption of arteriotomy closure devices.
  • The use of Arteriotomy Closure Devices is recommended to patients undergoing acute myocardial infarction, neurovascular interventions and endovascular procedures for peripheral vascular diseases.

FineHeart Achieves Milestone for Its Miniaturized Heart Pump Technology With Successful Completion of 30-day Preclinical Study

Tuesday, October 20, 2020 - 4:00pm

FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.

Key Points: 
  • FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.
  • The success of this 30-day in vivo study is a significant milestone for FineHeart as we work towards first-in-human clinical trials and prove ICOMS technology as a potential game-changer in saving patients from heart failure, said Arnaud Mascarell, CEO and Founder, FineHeart.
  • Hospital readmission rates following LVAD surgery is staggering, with patients being re-admitted two to five times in the first six months following LVAD surgery.
  • Our team has developed a technology to mitigate complications and issues, such as rehospitalization.

Global Bioabsorbable Stents Market Forecast 2020-2025 Featuring Key Players - Abbot Laboratories, Elixir Medical, Reva Medical, Kyoto Medical Planning - ResearchAndMarkets.com

Tuesday, October 20, 2020 - 9:28am

To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.

Key Points: 
  • To overcome these roadblocks biodegradable stents came into existence in the recent years and is expected to considerably replace traditional stents.
  • The bioabsorbable stents market is classified on the basis of material used for manufacturing the products including polymeric and metallic.
  • Metal bioabsorbable stents are luring the medical device providers as they have the potential to perform similarly to stainless steel metal stents.
  • The key players in bioabsorbable stents market include:

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

Saturday, October 17, 2020 - 5:00pm

The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.

Key Points: 
  • The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.
  • The high TLF reported in both OPTIMIZE treatment groups is driven by the 25% of study subjects assessed peri-procedurally with high-sensitivity-troponin.
  • We are deeply grateful to each and every one of the patients, investigative team members and support personnel contributing to the OPTIMIZE study.
  • Headquartered in New Providence, New Jersey, Svelte Medical Systems ( www.sveltemedical.com ) is a privately-held company engaged in the development of highly deliverable balloon expandable stents.

Global Peripheral Stents Market Insights to 2024 - Players Include Abbott, Biotronik and Boston Medical Among Others - ResearchAndMarkets.com

Friday, October 16, 2020 - 3:26pm

The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peripheral Stents Market" report has been added to ResearchAndMarkets.com's offering.
  • This report was developed using extensive primary and secondary research by the publisher's analysts.
  • Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market share for the top suppliers by product segment.
  • Devices in this global market analysis include peripheral vascular stents, iliac artery stents, biliary stents, tracheobronchial stents.

Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

Friday, October 16, 2020 - 1:05pm

Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.

Key Points: 
  • Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.
  • This study suggests that in right heart failure, reducing the time between shock onset and initiation of Impella RP is a key element of proper patient support.
  • A second study presented at TCT aims to help clinicians identify early triggers of right heart failure.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

Friday, October 16, 2020 - 12:05pm

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.

Key Points: 
  • Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI.
  • Researchers found an 18% relative improvement in overall survival in the recent cohort, indicating an associated benefit to placing Impella pre-PCI.
  • It found that placing Impella pre-PCI in AMICS patients is associated with higher survival than placing Impella post-PCI, especially in women.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (T

Thursday, October 15, 2020 - 9:30pm

The findings of benefit in at-risk patients with prior PCI are consistent with previously presented data on overall reductions in first and total coronary revascularization events of 34% and 36%, respectively.

Key Points: 
  • The findings of benefit in at-risk patients with prior PCI are consistent with previously presented data on overall reductions in first and total coronary revascularization events of 34% and 36%, respectively.
  • The REDUCE-IT PCI analysis looked at 3,408 (41.7%) of patients enrolled in REDUCE-IT who had undergone a prior PCI.
  • Coronary revascularization procedures, such as stenting, are invasive, carry multiple risks, and can have significant direct and indirect costs.
  • Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations.

DEFINE PCI study one-year data show potential of treating residual ischemia to improve clinical outcomes for coronary stent patients

Thursday, October 15, 2020 - 6:00pm

The DEFINE PCI study assessed the level of residual ischemia, or reduced blood flow to the heart muscle, found in patients after a percutaneous coronary intervention (PCI), an image-guided, minimally invasive treatment to open coronary artery blockages.

Key Points: 
  • The DEFINE PCI study assessed the level of residual ischemia, or reduced blood flow to the heart muscle, found in patients after a percutaneous coronary intervention (PCI), an image-guided, minimally invasive treatment to open coronary artery blockages.
  • The blinded acute data of DEFINE PCI revealed that 24% of patients with angiographically successful PCI still had residual ischemia.
  • The DEFINE PCI one-year data release shows that patients whose baseline ischemia was more effectively treated (post-PCI iFR 0.95) had improved outcomes and less recurrent angina (chest pain) at one year.
  • The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.

Strides in Interventional Radiology Market Open New Pathways for Management of Cancer, Global Valuation to Clock CAGR of 5.2% from 2019 to 2027

Wednesday, October 14, 2020 - 3:30pm

Growing clinical relevance of interventional radiology in angioplasty and stent placement has helped propel the market growth.

Key Points: 
  • Growing clinical relevance of interventional radiology in angioplasty and stent placement has helped propel the market growth.
  • The global valuation of the interventional radiology market was pegged at US$ 16.4 Bn in 2018, and is forecast to expand at CAGR of 5.2% from 2019 to 2027.
  • Growing clinical relevance of optical coherence tomography (OCT) for interventional cardiologists is boosting the prospects in interventional radiology market.
  • Rise in image-guided therapeutic interventions in emerging economies of the region has also helped cement the potential of the Asia Pacific interventional radiology market.